TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1350400
Drug: Superficial radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Superficial radiotherapy (SRT) - three fractionated doses of 150 cGy (90 kV, 5 mA, 1.00 mm aluminium filter)
Study: 30133478
Drug: NASVAC (therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: NASVAC (therapeutic vaccine containing HBsAg and HBcAg, 100 μg each, administered in 2 cycles of 5 doses)
Study: 30133478
Drug: Peg‐IFN (48
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peg‐IFN (48 subcutaneous injections of Peg‐IFN alfa 2b, 180 μg per dose, every week for 48 weeks)
Study: 26728480
Drug: PPV plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPV plus oral low‐dose CPA (50 mg/day)
Study: 16649872
Drug: High-dose nicotine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose nicotine patch (35 mg)
Study: 16288408
Drug: Interferon and
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon and ribavirin combination treatment
Study: 1970032
Drug: Oestrogen-progesterone (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestrogen-progesterone (0.05 mg ethinyloestradiol plus 1 mg norethisterone daily for 6 months)
Study: 21610207
Drug: GSK1521498 (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1521498 (oral solution and capsule formulations)
Study: 21610207
Drug: GSK1521498 (10-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1521498 (10-150 mg single doses)
Study: 15192648
Drug: Trientine hydrochloride
Normalized name: Trientine Hydrochloride
DrugBank: Triethylenetetramine (DB06824)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Trientine hydrochloride (250 mg daily before a meal)
Study: 15192648
Drug: Trientine hydrochloride
Normalized name: Trientine Hydrochloride
DrugBank: Triethylenetetramine (DB06824)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Trientine hydrochloride (750 mg daily, divided into 3 doses)
Study: 11756065
Drug: Zinc (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc (20 mg/d for 14 days)
Study: 29446830
Drug: Ketone monoester
Normalized name: Ketonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketone monoester (Kme) supplement (ΔG®; TΔS Ltd, UK, Oxford, UK; 0.45 ml kg-1 body weight)
Study: 2126745
Drug: Morphine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine administration in the TPN group
Study: 2126745
Drug: Morphine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine administration in the non-TPN group
Study: 6794167
Drug: No radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: No radiation therapy (control group)
Study: 28124569
Drug: Double percutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double percutaneous aspiration injection (DPAI)
Study: 15179967
Drug: Acamprosate, 1332-1998
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acamprosate, 1332-1998 mg/day
Study: 15179967
Drug: No anti-relapse
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anti-relapse medication (control group)
Study: 8527687
Drug: Experimental controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental controlled release tablet containing pseudoephedrine
Study: 8527687
Drug: Marketed controlled
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marketed controlled release pseudoephedrine capsule
Study: 8527687
Drug: Experimental controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental controlled release tablet containing pseudoephedrine with guaifenesin
Study: 697082
Drug: Bupivacaine epidural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine epidural anesthesia (168 +/- 7 mg)
Study: 17285269
Drug: Propolis (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propolis (500 mg daily)
Study: 15121650
Drug: Enhanced counseling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced counseling and support treatment
Study: 11704076
Drug: Extraocular light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extraocular light therapy (15 patients, 4 M, 11 F)
Study: 9382120
Drug: Pneumococcal and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumococcal and influenza vaccines (PI group)
Study: 9382120
Drug: Influenza vaccine
Normalized name: Influenza vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza vaccine alone (I group)
Study: 2554722
Drug: HF (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: HF (high fiber diet with 55 g fiber/day)
Study: 2554722
Drug: HFS (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFS (high fiber diet with 55 g fiber/day and 15 g sucrose three times daily)
Study: 2554722
Drug: Control (usual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (usual diet with about 30 g fiber/day)
Study: 240014
Drug: Early continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early continuous negative pressure (CNP) treatment before PaO2 < 50 mm Hg on 70% oxygen
Study: 240014
Drug: Early continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early continuous negative pressure (CNP) treatment
Study: 240014
Drug: Delayed continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed continuous negative pressure (CNP) treatment
Study: 16198519
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens 0.625 mg plus medroxyprogesterone acetate 5 mg (CEE/MPA, n=38)
Study: 16198519
Drug: 17beta‐estradiol 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17beta‐estradiol 2 mg plus norethisterone acetate 1 mg (E2/NETA, n=44)
Study: 16198519
Drug: 17beta‐estradiol 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17beta‐estradiol 1 mg plus norethisterone acetate 0.5 mg (low E2/NETA, n=50)
Study: 8214698
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion supplemented with an epidural block with bupivacaine (Group B)
Study: 8214698
Drug: Alfentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil infusion intravenously (Group A)
Study: 9378150
Drug: Cisplatin and
Normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin and cyclophosphamide plus doxorubicin (40 mg/m2)
Study: 9378150
Drug: Cisplatin and
Normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin and cyclophosphamide plus doxorubicin (50 mg/m2)
Study: 3877279
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion at 3 mg/kg/h
Study: 3877279
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion at 6 mg/kg/h
Study: 3877279
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion at 9 mg/kg/h
Study: 3877279
Drug: All infusion
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All infusion rates (3, 6, 9 mg/kg/h)
Study: 29654415
Drug: Ribociclib (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribociclib (600 mg/day; 3-weeks-on/1-week-off) plus letrozole (2.5 mg/day)
Study: 31785169
Drug: Daylight photodynamic
Normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daylight photodynamic therapy (DPDT)
Study: 26843523
Drug: Artificial white
Normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial white light photodynamic therapy (AWLPDT)
Study: 24709267
Drug: Nutritional supplementation
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplementation during the intensive phase of TB treatment
Study: 12437253
Drug: G-100 (<=
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-100 (<= 100 mL/d, n = 44)
Study: 12437253
Drug: G-150 (<=
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-150 (<= 150 mL/d, n = 58)
Study: 12437253
Drug: G-200 (<=
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-200 (<= 200 mL/d, n = 37)
Study: 12437253
Drug: G-val (prospective
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-val (prospective validation group, n = 91)
Study: 10344212
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of finasteride plus terazosin (C)
Study: 7531900
Drug: Finasteride (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride (5 mg/d) for 12 months
Study: 1682247
Drug: Vecuronium (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium (0.1 mg/kg body weight)
Study: 1682247
Drug: Pancuronium (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancuronium (0.1 mg/kg body weight)
Study: 7159500
Drug: Guar (15.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guar (15.6 g/day) + Bezafibrate (600 mg/day)
Study: 7159500
Drug: Bezafibrate (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bezafibrate (600 mg/day) alone
Study: 30536182
Drug: Metformin (M)
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (M) 2000 mg/day plus NPLD 60 mg/m2 + cyclophosphamide 600 mg/m2 × 8 cycles Q21 days (arm A)
Study: 30536182
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (NPLD/C) (arm B)
Study: 30536182
Drug: Metformin (M)
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (M) in patients with HOMA index < 2.5
Study: 30536182
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone in patients with HOMA index ≥ 2.5
Study: 30536182
Drug: Metformin (M)
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (M) plus chemotherapy (arm A)
Study: 30536182
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (arm B)
Study: 30536182
Drug: Metformin (M)
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (M) induced diarrhea (G2)
Study: 27907817
Drug: Featback with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Featback with low‐intensity (weekly) therapist support
Study: 24848974
Drug: 12 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 g/d Soluble maize fibre (SCF)
Study: 24848974
Drug: 0 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g/d Soluble maize fibre (Control treatment)
Study: 18394931
Drug: Gliclazide treatment
Normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide treatment in Type 2 diabetic patients
Study: 18394931
Drug: Healthy controls
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy controls (no gliclazide treatment)
Study: 15817859
Drug: Selenium as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium as selenomethionine and selenite (highest doses)
Study: 10597397
Drug: 7-day triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day triple therapy with pantoprazole, 40 mg bid; clarithromycin, 250 mg bid; and metronidazole, 400 mg bid preceded by pantoprazole, 40 mg (P-PCM)
Study: 10597397
Drug: 7-day triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day triple therapy with pantoprazole, 40 mg bid; clarithromycin, 250 mg bid; and metronidazole, 400 mg bid followed by pantoprazole, 40 mg (PCM-P)
Study: 7489182
Drug: Lexipafant 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lexipafant 60 mg intravenously for 3 days
Study: 2201157
Drug: alpha 2‐interferon
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha 2‐interferon administered until day 7 of jaundice
Study: 2201157
Drug: common therapy
Normalized name: Common carp
DrugBank: Common carp (DB10614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: common therapy (control group)
Study: 2201157
Drug: alpha 2‐interferon
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha 2‐interferon administered after day 6 of jaundice
Study: 27936526
Drug: Topical 1%
Normalized name: fluoride topical 1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 1% diclofenac + 3% menthol gel (administered via tube or roll-on device, 4 g applied 4 times daily)
Study: 27936526
Drug: Topical 1%
Normalized name: fluoride topical 1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 1% diclofenac sodium gel (Voltaren Gel, 4 g applied 4 times daily)
Study: 27936526
Drug: Oral diclofenac
Normalized name: diclofenac Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diclofenac sodium tablets (50 mg, 3 times daily)
Study: 27936526
Drug: Topical 1%
Normalized name: fluoride topical 1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 1% diclofenac + 3% menthol gel
Study: 27936526
Drug: Voltaren Gel
Normalized name: Diclofenac Sodium 1% Topical application Gel/Jelly [VOLTAREN GEL]
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Voltaren Gel
Study: 10838532
Drug: Initial surgical
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial surgical resection vs resection after initial chemotherapy
Study: 8471405
Drug: Losartan (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (25 to 200 mg)
Study: 8471405
Drug: Losartan (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (multiple dosing for 7 days)
Study: 3861605
Drug: Enoxacin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxacin treatment
Study: 31880758
Drug: LPS Adsorber
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPS Adsorber therapy
Study: 31880758
Drug: Sham Adsorber
Normalized name: diphtheria toxoid adsorbed
DrugBank: Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (DB10584)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham Adsorber therapy
Study: 18219452
Drug: Trigonella foenum‐graecum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trigonella foenum‐graecum L. total saponins (TFGs)
Study: 10924776
Drug: Spironolactone (MR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (MR antagonist), treated for 8 days
Study: 8651091
Drug: Heparin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin plus urokinase (250 U heparin plus 5,000 U urokinase per minute)
Study: 8651091
Drug: Heparin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (250 U heparin per minute)
Study: 8651091
Drug: Heparin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin plus urokinase
Study: 1848421
Drug: Vindesine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vindesine (3 mg/m2, day 1, 8, 15) plus three cisplatins (35 mg/m2, day 1, 8, 15)
Study: 1848421
Drug: Vindesine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vindesine (3 mg/m2, day 1, 8, 15) plus one cisplatin (80 mg/m2, day 1)
Study: 20211949
Drug: Drainage, irrigation,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drainage, irrigation, and fibrinolytic therapy (DRIFT)
Study: 20211949
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (tapping off cerebrospinal fluid)
Study: 12359681
Drug: Quality improvement
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quality improvement programs for depression (training experts and nurse specialists, access to nurse specialists for medication follow-up, access to psychotherapists)
Study: 7725384
Drug: Vicks inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vicks inhaler (double dosage)
Study: 7725384
Drug: Vicks inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vicks inhaler (recommended dosage)
Study: 7032554
Drug: Verapamil, 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil, 120 mg three times a day
Study: 7032554
Drug: Nifedipine, 20
Normalized name: Nifedipine, 20 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine, 20 mg three times a day
Study: 25988317
Drug: Memantine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine (5 mg/day)
Study: 17805214
Drug: Aripiprazole 9.4+/‐4.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole 9.4+/‐4.2 mg/day
Study: 15542042
Drug: Raloxifene 60
Normalized name: raloxifene 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene 60 mg/day and 120 mg/day (pooled)
Study: 3888730
Drug: Limbitrol (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Limbitrol (25 mg amitriptyline and 10 mg chlordiazepoxide)
Study: 30679302
Drug: Exenatide plus
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide plus basal insulin
Study: 27617661
Drug: Olaparib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib (400 mg twice a day)
Study: 27617661
Drug: Olaparib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib (400 mg twice a day) in patients with BRCAm
Study: 27617661
Drug: Olaparib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib (400 mg twice a day) in patients with BRCA wild-type
Study: 21959915
Drug: Cognitive-behavioural group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural group therapy
Study: 20151799
Drug: SRP plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP plus simvastatin (SMV) 1.2 mg
Study: 18849894
Drug: Second-generation oral
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second-generation oral antipsychotics (short-term, 5 days)
Study: 16009795
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy (atorvastatin 80 mg/d)
Study: 16009795
Drug: Moderate therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate therapy (pravastatin 40 mg/d)
Study: 9920080
Drug: Micronized 17beta‐estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized 17beta‐estradiol [0.5 mg/day Estrace (E2)]
Study: 9920080
Drug: 1500 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg/day elemental calcium, given as carbonate plus vitamin D (800 IU/day; Ca+D)
Study: 9920080
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Ca+D and E2)
Study: 2345485
Drug: Cyproheptadine (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproheptadine (16 mg)
Study: 27416915
Drug: Sofosbuvir (SOF)/ledipasvir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir (SOF)/ledipasvir for 12 weeks in treatment experienced patients without cirrhosis
Study: 27416915
Drug: Paritaprevir/r, ombitasvir,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paritaprevir/r, ombitasvir, dasabuvir ± ribavirin for 12 weeks in treatment experienced patients without cirrhosis
Study: 27416915
Drug: Sofosbuvir (SOF)/simeprevir/1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir (SOF)/simeprevir/1200 mg/d ribavirin for 12 weeks in re-treated cirrhotic individuals
Study: 21272454
Drug: Interferon a‐1b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon a‐1b combined with lamivudine (100 mg, P.O., q.d. for 6-12 months or longer)
Study: 17605253
Drug: Artificial dermis
Normalized name: COLOR,ARTIFICIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial dermis and recombinant bFGF2 spray, applied twice a day after immersion bath, dressing changed every other day or every 2 days
Study: 11483170
Drug: Cognitive task
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive task involving sequential learning, explicit processing, and working memory
Study: 7522906
Drug: High-dose aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose aprotinin (2 x 10(6) KI units intravenous bolus and 0.5 x 10(6) KI units h‐1 plus 2 x 10(6) KI units into pump prime)
Study: 7522906
Drug: Patient group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient group (aprotinin 10(6) KI units intravenous bolus plus 10(6) KI units added to pump prime)
Study: 25698173
Drug: Trichuris suis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trichuris suis ova therapy, 2500 ova orally every second week for 12 weeks
Study: 17922185
Drug: Aromatase inhibitors
Normalized name: Aromatase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitors (exemestane and letrozole)
Study: 16820790
Drug: Cyclophosphamide (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide (750 mg/m2, 13 pulses in 2 years) combined with oral prednisone (CY)
Study: 16820790
Drug: Azathioprine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine (2 mg/kg/day in 2 years) combined with intravenous pulses of methylprednisolone (3 x 3 pulses of 1000 mg) and oral prednisone (AZA)
Study: 1492307
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment modes
Study: 2993690
Drug: SBT/CPZ (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: SBT/CPZ (0.5 g SBT + 0.5 g CPZ, 2 times/day)
Study: 2993690
Drug: CZX (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: CZX (1.0 g, 2 times/day)
Study: 31729647
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy group (target serum UA level ≥ 4.0 mg/dL, < 5.0 mg/dL)
Study: 31729647
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy group (serum UA level ≥ 6.0 mg/dL, < 7.0 mg/dL)
Study: 31729647
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy group
Study: 28065445
Drug: Colchicine (1mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (1mg once daily for 1 month plus optimal medical treatment)
Study: 28065445
Drug: Control (optimal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (optimal medical treatment only)
Study: 21493743
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (prednisolone, azathioprine, heparin‐warfarin, and dipyridamole)
Study: 21493743
Drug: Control therapy
Normalized name: Benzoyl Peroxide;Salicylic Acid;Vitamin E 8%; 2%; 5% Topical application Kit [INOVA 8/2 ACNE CONTROL THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control therapy (heparin‐warfarin and dipyridamole)